Cardurion pharmaceuticals llc
WebA foundational new treatment for patients with both types of chronic heart failure. A next generation neurohumoral drug, with improved efficacy compared with Entresto®. April 15, 2024 07:30 AM Eastern Daylight Time. BOSTON – (BUSINESS WIRE) – … WebAug 16, 2024 · CAMBRIDGE, MASS. – [August 16, 2024] – Cardurion Pharmaceuticals, a biotechnology company focused on the development of novel, next-generation therapeutics for the treatment of cardiovascular diseases, today announced the appointment of industry leader, Jeb Keiper, as an independent member of its Board of Directors. Mr.
Cardurion pharmaceuticals llc
Did you know?
WebHeadquarters Location. 78 Blanchard Road Suite 200. Burlington, Massachusetts, 01803, United States. 617-863-8088 WebOct 27, 2024 · Boston, MA, October 27, 2024 – Cardurion Pharmaceuticals, Inc. (“Cardurion” or “the Company”), a clinical-stage biotechnology company focused on the discovery and development of novel, next-generation therapeutics for the treatment of heart failure and other cardiovascular diseases, today announced it has received a private …
WebLegal Name Cardurion Pharmaceuticals LLC; Company Type For Profit; Contact Email [email protected]; Phone Number 617-996-1433 WebJan 15, 2024 · In June 2024, Jeb was elected as an independent director to the board of Cardurion Pharmaceuticals, LLC, a clinical-stage cardiovascular diseases company based in Cambridge, MA. Prior to Nimbus,...
WebNov 10, 2024 · Cardurion Pharmaceuticals, LLC entered into an asset purchase agreement to acquire Tovinontrine (IMR-687) and All of the Assets Related to PDE9 Program from IMARA Inc. (NasdaqGS:IMRA) for approximately $95 on September 6, 2024. As consideration for the Asset Sale, in addition to $250,000 previously paid by … WebSep 7, 2024 · September 7, 2024, 9:05 AM · 1 min read Imara Inc (NASDAQ: IMRA) has agreed to divest tovinontrine (IMR-687) and all other assets related to its PDE9 program to Cardurion Pharmaceuticals Inc.
WebCardurion Pharmaceuticals has raised a total of $343.2M in funding over 5 rounds. Their latest funding was raised on Dec 30, 2024 from a Debt Financing round. Cardurion Pharmaceuticals is funded by 3 investors. Polaris Partners and Bain Capital are the most recent investors. Funding Rounds Number of Funding Rounds 5 Total Funding Amount …
cinema pj stateWebNov 20, 2024 · About Cardurion Pharmaceuticals. Cardurion Pharmaceuticals is a biotechnology company with both clinical and preclinical programs focused on the development of novel, next-generation therapeutics ... cinema platja d\u0027aroWebRebecca Frey is Cardurion’s consulting chief operating officer. She began working as a member of Cardurion’s executive team in 2024 and transitioned to a consulting capacity in 2024. During her tenure, Rebecca … cinema patio hojeWebPTC names Matthew Klein as chief development officer; plus Cardurion, Sangamo, TCR2, Five Prime and more ...and mitochondrial therapies; Pauwels was SVP and general … cinema pink boluWebSep 20, 2024 · Cardurion Pharmaceuticals is a biotechnology company with both clinical and preclinical programs focused on the development of novel, next-generation therapeutics for the treatment of heart failure and other cardiovascular diseases. cinema planet jerusalemWebCardurion Pharmaceuticals. Research & Development · Massachusetts, United States · <25 Employees . Cardurion Pharmaceuticals is a biotechnology company focused on … cinema plaza balikpapanWebCardurion Pharmaceuticals, Inc. Street Address 1 Street Address 2; ONE LINCOLN STREET: City State/Province/Country ZIP/PostalCode Phone Number of Issuer; … cinema paradiso katherine jenkins album